<SEC-DOCUMENT>0001640334-19-000755.txt : 20190506
<SEC-HEADER>0001640334-19-000755.hdr.sgml : 20190506
<ACCEPTANCE-DATETIME>20190506172430
ACCESSION NUMBER:		0001640334-19-000755
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190430
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
FILED AS OF DATE:		20190506
DATE AS OF CHANGE:		20190506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		19800425

	BUSINESS ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inmb_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>inmb_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="center"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="3">UNITED STATES</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">Washington, D.C. 20549</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>CURRENT REPORT</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported): <b>April 30, 2019</b></p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="40%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top"> <p style="MARGIN: 0px" align="center"><b><font size="5">INMUNE BIO INC.</font></b></p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in charter)</p></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>001-38793</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>47-5205835</b></p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="center">(State or other jurisdiction</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(Commission</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(IRS Employer</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="center">of incorporation)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">File Number)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">Identification No.)</p></td></tr></table> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>1224 Prospect Street, Suite 150, La Jolla, CA 92037</u></b></p> <p style="MARGIN: 0px" align="center">(Address of Principal Executive Offices) (Zip Code)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>(858) 964 3720</u></b></p> <p style="MARGIN: 0px" align="center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>Not Applicable</u></b></p> <p style="MARGIN: 0px" align="center">(Former Name or Former Address, If Changed Since Last Report)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u>&nbsp;General Instruction A.2. below):</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td width="4%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top" width="4%"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Emerging growth company&nbsp;<font face="Wingdings">x</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<font face="Wingdings">&#168;</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px"><b>Item 1.01 Entry into a Material Definitive Agreement</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">INmune Bio Inc. (the &#8220;Company&#8221;) entered into Securities Purchase Agreements (the &#8220;Securities Purchase Agreements&#8221;) with five accredited investors. </p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Pursuant to the Securities Purchase Agreements, the Company sold &nbsp;(the &#8220;Offering&#8221;) an aggregate of 460,545 shares (&#8220;Shares&#8221;) of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) at a purchase price of $9.00 per share and received proceeds of $4,144,900.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">The investors in the Offering included Dr. Raymond J. Tesi, the Company&#8217;s Chief Executive Officer and a member of the Company&#8217;s &nbsp;board of directors who purchased 11,100 Shares in the Offering for gross proceeds of $99,900 and &nbsp;David Moss, the Company&#8217;s Chief Financial Officer, Secretary and Treasurer who purchased 5,000 Shares in the Offering for gross proceeds of $45,000.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Pursuant to the Securities Purchase Agreements, within 30 days after the effectiveness of a registration statement for the resale of securities issued to a certain investor as set forth in the Securities Purchase Agreements the Company agreed to file a registration statement with the Securities and Exchange Commission to register the shares of Common Stock issued pursuant to the Securities Purchase Agreements.</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>Item 3.02 Unregistered Sales of Equity Securities</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="MARGIN: 0px" align="justify">See Item 1.01 which is incorporated by reference, in its entirety, into this Item 3.02.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">The Shares sold in the Offering described in Item 1.01 above were not registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the securities laws of any state, and were offered and sold in reliance on the exemption from registration afforded by Section 4(a)(2) and Rule 506(b) of Regulation D promulgated under the Securities Act, since, among other things, the transactions did not involve a public offering and the securities were acquired for investment purposes only and not with a view to or for sale in connection with any distribution thereof.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="center"> <table id="pagebreakc6219ef7-771a-4b74-9c32-83bba90d8610" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>SIGNATURE</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top" colspan="2"> <p style="MARGIN: 0px" align="justify"><b>INMUNE BIO INC.</b></p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top" colspan="2"></td> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr> <tr height="15"> <td valign="top" width="50%"> <p style="MARGIN: 0px" align="justify">Date: May 6, 2019</p></td> <td valign="top" width="3%"> <p style="MARGIN: 0px" align="justify">By:</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"><em>/s/ David Moss</em></td> <td width="12%"></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">David Moss</p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Chief Financial Officer</p></td> <td></td></tr></table> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">3</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
